📰 Evofem Bioscience News
Page 4 - Evofem Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Evofem Bioscience. Real-time updates on events, politics, business and more.
April 24, 2022
Brokerages expect that Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) will post $4.23 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Evofem Biosciences’ earnings. The highest sales estimate is $5.30 million and the lowest is $3.30 million. Evofem Biosciences posted sales of $1.11 million during the […]
April 19, 2022
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the Journal of Sexual Medicine, a peer-reviewed medical journal, published data...
April 11, 2022
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Karina Fedasz as its Head of Business Development. At Evofem,...
April 7, 2022
/PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) ("Evofem" and the "Company"), a commercial-stage biopharmaceutical company, today announced the Nasdaq...
March 31, 2022
Phase 2B/3 AMPREVENCE Clinical Trial Concluded with Women Experiencing a 50 Percent Risk Reduction in Chlamydia Trachomatis (chlamydia) and a 78 Percent Risk...
March 31, 2022
--Evofem Biosciences, Inc., today presented data at the Academy of Managed Care Pharmacy annual meeting showing EVO100 provided a significant decrease in gonorrhea and chlamydia infections in women as well as additional patient health outcomes related to satisfaction with use of the investigational product. "Findings from these analyses demonstrate the...
March 16, 2022
Equities analysts expect that Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) will report sales of $4.40 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Evofem Biosciences’ earnings, with the highest sales estimate coming in at $5.30 million and the lowest estimate coming in at $3.51 million. Evofem Biosciences posted […]
March 3, 2022
/PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and...
February 9, 2022
/PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that the U.S. Food and Drug Administration (FDA) has awarded "Qualified Infectious...
February 9, 2022
SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., announced today that the U.S. Food and Drug Administration has awarded Qualified Infectious Disease Product Designation to... | February 9, 2022